Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,735
archived clinical trials in
Psoriasis

Molecular and Cellular Characterization of Spongiotic Dermatitis
Molecular and Cellular Characterization of Spongiotic Dermatitis
Status: Archived
University of California, Davis Department of Dermatology
mi
from
Sacramento, CA
Molecular and Cellular Characterization of Spongiotic Dermatitis
Molecular and Cellular Characterization of Spongiotic Dermatitis
Status: Archived
Updated: 1/1/1970
University of California, Davis Department of Dermatology
mi
from
Sacramento, CA
Safety Study of AMG 157 in Healthy Subjects and Subjects With Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 157 in Healthy Subjects and Subjects With Moderate to Severe Atopic Dermatitis
Status: Archived
Clinical Research Facility
mi
from
Phoenix, AZ
Safety Study of AMG 157 in Healthy Subjects and Subjects With Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 157 in Healthy Subjects and Subjects With Moderate to Severe Atopic Dermatitis
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Phoenix, AZ
Safety Study of AMG 157 in Healthy Subjects and Subjects With Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 157 in Healthy Subjects and Subjects With Moderate to Severe Atopic Dermatitis
Status: Archived
Clinical Research Facility
mi
from
San Diego, CA
Safety Study of AMG 157 in Healthy Subjects and Subjects With Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 157 in Healthy Subjects and Subjects With Moderate to Severe Atopic Dermatitis
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
San Diego, CA
Safety Study of AMG 157 in Healthy Subjects and Subjects With Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 157 in Healthy Subjects and Subjects With Moderate to Severe Atopic Dermatitis
Status: Archived
Clinical Research Facility
mi
from
Henderson, NV
Safety Study of AMG 157 in Healthy Subjects and Subjects With Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 157 in Healthy Subjects and Subjects With Moderate to Severe Atopic Dermatitis
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Henderson, NV
Safety Study of AMG 157 in Healthy Subjects and Subjects With Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 157 in Healthy Subjects and Subjects With Moderate to Severe Atopic Dermatitis
Status: Archived
Clinical Research Facility
mi
from
Bend, OR
Safety Study of AMG 157 in Healthy Subjects and Subjects With Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 157 in Healthy Subjects and Subjects With Moderate to Severe Atopic Dermatitis
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Bend, OR
Safety and Pharmacokinetics (PK) of Alefacept in Adolescent Subjects With Moderate to Severe Psoriasis
A Phase 2, Single-Arm Study to Evaluate the Safety and Pharmacokinetics of Alefacept in Adolescent Subjects With Moderate to Severe Psoriasis [ISN 0485-CL-0004]
Status: Archived
Clinical Trial Facility
mi
from
Santa Clara, CA
Safety and Pharmacokinetics (PK) of Alefacept in Adolescent Subjects With Moderate to Severe Psoriasis
A Phase 2, Single-Arm Study to Evaluate the Safety and Pharmacokinetics of Alefacept in Adolescent Subjects With Moderate to Severe Psoriasis [ISN 0485-CL-0004]
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Santa Clara, CA
Safety and Pharmacokinetics (PK) of Alefacept in Adolescent Subjects With Moderate to Severe Psoriasis
A Phase 2, Single-Arm Study to Evaluate the Safety and Pharmacokinetics of Alefacept in Adolescent Subjects With Moderate to Severe Psoriasis [ISN 0485-CL-0004]
Status: Archived
Clinical Trial Facility
mi
from
Celebration, FL
Safety and Pharmacokinetics (PK) of Alefacept in Adolescent Subjects With Moderate to Severe Psoriasis
A Phase 2, Single-Arm Study to Evaluate the Safety and Pharmacokinetics of Alefacept in Adolescent Subjects With Moderate to Severe Psoriasis [ISN 0485-CL-0004]
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Celebration, FL
Safety and Pharmacokinetics (PK) of Alefacept in Adolescent Subjects With Moderate to Severe Psoriasis
A Phase 2, Single-Arm Study to Evaluate the Safety and Pharmacokinetics of Alefacept in Adolescent Subjects With Moderate to Severe Psoriasis [ISN 0485-CL-0004]
Status: Archived
Clinical Trial Facility
mi
from
Louisville, KY
Safety and Pharmacokinetics (PK) of Alefacept in Adolescent Subjects With Moderate to Severe Psoriasis
A Phase 2, Single-Arm Study to Evaluate the Safety and Pharmacokinetics of Alefacept in Adolescent Subjects With Moderate to Severe Psoriasis [ISN 0485-CL-0004]
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Louisville, KY
Safety and Pharmacokinetics (PK) of Alefacept in Adolescent Subjects With Moderate to Severe Psoriasis
A Phase 2, Single-Arm Study to Evaluate the Safety and Pharmacokinetics of Alefacept in Adolescent Subjects With Moderate to Severe Psoriasis [ISN 0485-CL-0004]
Status: Archived
Clinical Trial Facility
mi
from
Lima, OH
Safety and Pharmacokinetics (PK) of Alefacept in Adolescent Subjects With Moderate to Severe Psoriasis
A Phase 2, Single-Arm Study to Evaluate the Safety and Pharmacokinetics of Alefacept in Adolescent Subjects With Moderate to Severe Psoriasis [ISN 0485-CL-0004]
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Lima, OH
Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris
Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris
Status: Archived
Center for Dermatology Clinical Research
mi
from
Fremont, CA
Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris
Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris
Status: Archived
Updated: 1/1/1970
Center for Dermatology Clinical Research
mi
from
Fremont, CA
Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris
Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris
Status: Archived
Rady Children's Hospital
mi
from
San Diego, CA
Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris
Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris
Status: Archived
Updated: 1/1/1970
Rady Children's Hospital
mi
from
San Diego, CA
Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris
Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris
Status: Archived
Ameriderm Research
mi
from
Ormond Beach, FL
Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris
Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris
Status: Archived
Updated: 1/1/1970
Ameriderm Research
mi
from
Ormond Beach, FL
Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris
Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris
Status: Archived
University of Miami Hospital
mi
from
Miami, FL
Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris
Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris
Status: Archived
Updated: 1/1/1970
University of Miami Hospital
mi
from
Miami, FL
Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris
Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris
Status: Archived
Northwestern University
mi
from
Chicago, IL
Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris
Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris
Status: Archived
Updated: 1/1/1970
Northwestern University
mi
from
Chicago, IL
Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris
Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris
Status: Archived
St. Louis Medical Center
mi
from
St. Louis, MO
Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris
Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris
Status: Archived
Updated: 1/1/1970
St. Louis Medical Center
mi
from
St. Louis, MO
Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris
Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris
Status: Archived
Arlington Research Center
mi
from
Arlington, TX
Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris
Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris
Status: Archived
Updated: 1/1/1970
Arlington Research Center
mi
from
Arlington, TX
Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris
Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris
Status: Archived
Virginia Clinical Research, Inc.
mi
from
Norfolk, VA
Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris
Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris
Status: Archived
Updated: 1/1/1970
Virginia Clinical Research, Inc.
mi
from
Norfolk, VA
Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris
Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris
Status: Archived
DBA Dermatology Associates
mi
from
Seattle, WA
Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris
Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris
Status: Archived
Updated: 1/1/1970
DBA Dermatology Associates
mi
from
Seattle, WA
Comparison of Video-Based Versus Written Patient Education on Atopic Dermatitis
Comparison of Video-Based Versus Written Patient Education on Atopic Dermatitis
Status: Archived
University of California, Davis Department of Dermatology
mi
from
Sacramento, CA
Comparison of Video-Based Versus Written Patient Education on Atopic Dermatitis
Comparison of Video-Based Versus Written Patient Education on Atopic Dermatitis
Status: Archived
Updated: 1/1/1970
University of California, Davis Department of Dermatology
mi
from
Sacramento, CA
Narrowband UVB Phototherapy in the Treatment of Psoriasis Vulgaris
Mechanism of Action of Narrowband UVB Phototherapy in the Treatment of Psoriasis Vulgaris
Status: Archived
The Rockefeller University Hospital
mi
from
New York, NY
Narrowband UVB Phototherapy in the Treatment of Psoriasis Vulgaris
Mechanism of Action of Narrowband UVB Phototherapy in the Treatment of Psoriasis Vulgaris
Status: Archived
Updated: 1/1/1970
The Rockefeller University Hospital
mi
from
New York, NY
Cell Responses to IFN-gamma
Cellular Responses To Intradermal-Gamma (IFN-gamma) in Normal and Psoriatic Patients
Status: Archived
The Rockefeller University Hospital
mi
from
New York, NY
Cell Responses to IFN-gamma
Cellular Responses To Intradermal-Gamma (IFN-gamma) in Normal and Psoriatic Patients
Status: Archived
Updated: 1/1/1970
The Rockefeller University Hospital
mi
from
New York, NY
A Study to Assess the Effect of Ustekinumab (Stelara®) and Etanercept (Enbrel®) in Participants With Moderate to Severe Psoriasis (MK-0000-206)
A Clinical Trial to Assess the Effects of Ustekinumab and Etanercept on Skin and Blood Biomarkers of Psoriasis in Patients With Moderate to Severe Disease
Status: Archived
Center for Fertility and Women's Health
mi
from
New Britain, CT
A Study to Assess the Effect of Ustekinumab (Stelara®) and Etanercept (Enbrel®) in Participants With Moderate to Severe Psoriasis (MK-0000-206)
A Clinical Trial to Assess the Effects of Ustekinumab and Etanercept on Skin and Blood Biomarkers of Psoriasis in Patients With Moderate to Severe Disease
Status: Archived
Updated: 1/1/1970
Center for Fertility and Women's Health
mi
from
New Britain, CT
Effect of Pimecrolimus Cream on Cathelicidin Levels in Subjects With Eczema
A Three-week, Double-blind, Randomized Study to Evaluate the Effect of Pimecrolimus Cream 1% on Cathelicidin Expression in the Skin of Subjects With Atopic Dermatitis
Status: Archived
San Francisco General Hospital
mi
from
San Francisco, CA
Effect of Pimecrolimus Cream on Cathelicidin Levels in Subjects With Eczema
A Three-week, Double-blind, Randomized Study to Evaluate the Effect of Pimecrolimus Cream 1% on Cathelicidin Expression in the Skin of Subjects With Atopic Dermatitis
Status: Archived
Updated: 1/1/1970
San Francisco General Hospital
mi
from
San Francisco, CA
Comparison Between Asynchronous Online Care Model With Usual In Office Care for the Management of Atopic Dermatitis
Comparison Between Asynchronous Online Care Model for the Management of Atopic Dermatitis With That of Face-to-Face, Office Visits
Status: Archived
University of California, Davis Department of Dermatology
mi
from
Sacramento, CA
Comparison Between Asynchronous Online Care Model With Usual In Office Care for the Management of Atopic Dermatitis
Comparison Between Asynchronous Online Care Model for the Management of Atopic Dermatitis With That of Face-to-Face, Office Visits
Status: Archived
Updated: 1/1/1970
University of California, Davis Department of Dermatology
mi
from
Sacramento, CA
The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage
The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage in Individuals With Multiple Skin Conditions A Double-Blind, Placebo Controlled Comparative Trial
Status: Archived
Dermatology Consultants Inc
mi
from
High Point, NC
The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage
The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage in Individuals With Multiple Skin Conditions A Double-Blind, Placebo Controlled Comparative Trial
Status: Archived
Updated: 1/1/1970
Dermatology Consultants Inc
mi
from
High Point, NC
Study to Assess VB-201 in Patients With Psoriasis
A Randomized, Double-Blind, 12-Week, Dose-Ranging Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral VB-201 in Patients With Moderate to Severe Plaque Psoriasis
Status: Archived
Alexa Kimball, MD, Massachusetts General and Brigham and Women's Hospital
mi
from
Boston, MA
Study to Assess VB-201 in Patients With Psoriasis
A Randomized, Double-Blind, 12-Week, Dose-Ranging Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral VB-201 in Patients With Moderate to Severe Plaque Psoriasis
Status: Archived
Updated: 1/1/1970
Alexa Kimball, MD, Massachusetts General and Brigham and Women's Hospital
mi
from
Boston, MA
Study to Assess VB-201 in Patients With Psoriasis
A Randomized, Double-Blind, 12-Week, Dose-Ranging Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral VB-201 in Patients With Moderate to Severe Plaque Psoriasis
Status: Archived
Mark Amster, MD, Boston Clinical Trials
mi
from
Boston, MA
Study to Assess VB-201 in Patients With Psoriasis
A Randomized, Double-Blind, 12-Week, Dose-Ranging Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral VB-201 in Patients With Moderate to Severe Plaque Psoriasis
Status: Archived
Updated: 1/1/1970
Mark Amster, MD, Boston Clinical Trials
mi
from
Boston, MA
Study to Assess VB-201 in Patients With Psoriasis
A Randomized, Double-Blind, 12-Week, Dose-Ranging Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral VB-201 in Patients With Moderate to Severe Plaque Psoriasis
Status: Archived
David L. Kreitzman, MD, P.C.
mi
from
Commack, NY
Study to Assess VB-201 in Patients With Psoriasis
A Randomized, Double-Blind, 12-Week, Dose-Ranging Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral VB-201 in Patients With Moderate to Severe Plaque Psoriasis
Status: Archived
Updated: 1/1/1970
David L. Kreitzman, MD, P.C.
mi
from
Commack, NY
Study to Assess VB-201 in Patients With Psoriasis
A Randomized, Double-Blind, 12-Week, Dose-Ranging Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral VB-201 in Patients With Moderate to Severe Plaque Psoriasis
Status: Archived
Craig Leonardi, MD, Central Dermatology
mi
from
St. Louis, MO
Study to Assess VB-201 in Patients With Psoriasis
A Randomized, Double-Blind, 12-Week, Dose-Ranging Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral VB-201 in Patients With Moderate to Severe Plaque Psoriasis
Status: Archived
Updated: 1/1/1970
Craig Leonardi, MD, Central Dermatology
mi
from
St. Louis, MO
Study to Assess VB-201 in Patients With Psoriasis
A Randomized, Double-Blind, 12-Week, Dose-Ranging Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral VB-201 in Patients With Moderate to Severe Plaque Psoriasis
Status: Archived
Julian MacKay Wiggan, MD, Columbia University Medical Center
mi
from
New York, NY
Study to Assess VB-201 in Patients With Psoriasis
A Randomized, Double-Blind, 12-Week, Dose-Ranging Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral VB-201 in Patients With Moderate to Severe Plaque Psoriasis
Status: Archived
Updated: 1/1/1970
Julian MacKay Wiggan, MD, Columbia University Medical Center
mi
from
New York, NY
Study to Assess VB-201 in Patients With Psoriasis
A Randomized, Double-Blind, 12-Week, Dose-Ranging Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral VB-201 in Patients With Moderate to Severe Plaque Psoriasis
Status: Archived
Mount Sinai Hospital
mi
from
New York, NY
Study to Assess VB-201 in Patients With Psoriasis
A Randomized, Double-Blind, 12-Week, Dose-Ranging Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral VB-201 in Patients With Moderate to Severe Plaque Psoriasis
Status: Archived
Updated: 1/1/1970
Mount Sinai Hospital
mi
from
New York, NY
Study to Assess VB-201 in Patients With Psoriasis
A Randomized, Double-Blind, 12-Week, Dose-Ranging Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral VB-201 in Patients With Moderate to Severe Plaque Psoriasis
Status: Archived
Bruce Strober, MD, New York University Medical Center, Dermatologic Associates
mi
from
New York, NY
Study to Assess VB-201 in Patients With Psoriasis
A Randomized, Double-Blind, 12-Week, Dose-Ranging Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral VB-201 in Patients With Moderate to Severe Plaque Psoriasis
Status: Archived
Updated: 1/1/1970
Bruce Strober, MD, New York University Medical Center, Dermatologic Associates
mi
from
New York, NY
Study to Assess VB-201 in Patients With Psoriasis
A Randomized, Double-Blind, 12-Week, Dose-Ranging Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral VB-201 in Patients With Moderate to Severe Plaque Psoriasis
Status: Archived
Steven Cohen, MD, Montefiore Medical Center, Dermatology
mi
from
New York, NY
Study to Assess VB-201 in Patients With Psoriasis
A Randomized, Double-Blind, 12-Week, Dose-Ranging Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral VB-201 in Patients With Moderate to Severe Plaque Psoriasis
Status: Archived
Updated: 1/1/1970
Steven Cohen, MD, Montefiore Medical Center, Dermatology
mi
from
New York, NY
Study to Assess VB-201 in Patients With Psoriasis
A Randomized, Double-Blind, 12-Week, Dose-Ranging Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral VB-201 in Patients With Moderate to Severe Plaque Psoriasis
Status: Archived
Joseph D. Sutton, MD, PC
mi
from
Suffern, NY
Study to Assess VB-201 in Patients With Psoriasis
A Randomized, Double-Blind, 12-Week, Dose-Ranging Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral VB-201 in Patients With Moderate to Severe Plaque Psoriasis
Status: Archived
Updated: 1/1/1970
Joseph D. Sutton, MD, PC
mi
from
Suffern, NY
Study to Assess VB-201 in Patients With Psoriasis
A Randomized, Double-Blind, 12-Week, Dose-Ranging Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral VB-201 in Patients With Moderate to Severe Plaque Psoriasis
Status: Archived
Kristina Callis-Duffin, MD, University of Utah
mi
from
Salt Lake City, UT
Study to Assess VB-201 in Patients With Psoriasis
A Randomized, Double-Blind, 12-Week, Dose-Ranging Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral VB-201 in Patients With Moderate to Severe Plaque Psoriasis
Status: Archived
Updated: 1/1/1970
Kristina Callis-Duffin, MD, University of Utah
mi
from
Salt Lake City, UT
Erlotinib for Treatment of Psoriasis
Phase II Randomized, Double-blind, Placebo-controlled, Two-arm Study to Evaluate the Safety and Efficacy of Erlotinib in the Treatment of Moderate to Severe Psoriasis
Status: Archived
Northwestern University
mi
from
Chicago, IL
Erlotinib for Treatment of Psoriasis
Phase II Randomized, Double-blind, Placebo-controlled, Two-arm Study to Evaluate the Safety and Efficacy of Erlotinib in the Treatment of Moderate to Severe Psoriasis
Status: Archived
Updated: 1/1/1970
Northwestern University
mi
from
Chicago, IL
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Birmingham, AL
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Birmingham, AL
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Santa Clara, CA
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Santa Clara, CA
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Denver, CO
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Denver, CO
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Newington, CT
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Newington, CT
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Celebration, FL
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Celebration, FL
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Centralia, IL
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Centralia, IL
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Jeffersonville, IN
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Jeffersonville, IN
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Metairie, LA
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Metairie, LA
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Chevy Chase, MD
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Chevy Chase, MD
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Boston, MA
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Boston, MA
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Hematology Oncology Associates of the Quad Cities
mi
from
Bettendorf, IA
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Updated: 1/1/1970
Hematology Oncology Associates of the Quad Cities
mi
from
Bettendorf, IA
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Clinical Trial Facility
mi
from
St Louis, MO
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
St Louis, MO
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Omaha, NE
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Omaha, NE
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Clinical Trial Facility
mi
from
West Orange, NJ
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
West Orange, NJ